MediMabBio won first place at Innovation Tiger 2025, a global biotech startup competition held at Shonan iPark in Japan. The final round featured 16 companies selected from 79 applicants across Korea, Japan, and Taiwan.
Dr. Peter Jianrui Liu, Co-Founder of OXcan, has decided to step down from his role as the Company\u2019s Founding CEO, to pursue other interests. He will remain a significant shareholder in the Company and therefore will retain every interest in the Company\u2019s development and success as an advisor.
We are delighted to welcome Professor Heidi Johansen-Berg to our Management Board, an expert in brain imaging and neuroplasticity, and a champion of innovation in the life sciences.
Dr Saggese will lead the expansion of the company's clinical trials with lead oncolytic immunotherapy THEO-260. THEO-260, is currently being investigated in patients with platinum-resistant ovarian cancer.
53.7% mean splicing correction observed following a single 15 mg/kg dose of PGN-EDODM1, with all patients showing an improvement in splicing. PGN-EDODM1 was generally well-tolerated at 15 mg/kg, with drug-related adverse events mild or moderate in severity
PepGen currently intends to use the net proceeds from this offering to fund its ongoing research and clinical development efforts, including the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, as well as for working capital and other general corporate purposes.
In the piece, CEO and co-founder Dr. Peter Jianrui Liu shares how the company is pioneering a non-invasive blood test for the early detection of lung cancer, using proteomics and AI/ML. Oxford Cancer Analytics' technology aims to change the way cancers are diagnosed, detecting disease earlier, cutting costs for health systems, and most importantly, saving lives.
We are delighted to welcome Omos Biosciences as the newest member of the BioEscalator community. The company has ambitious plans to transform cancer prevention by intervening at the pre-cancerous stage.
Follows successful completion of pre-clinical activities by Alchemab as part of an earlier licensing deal with Eli Lilly and Company for ATLX-1282. Financing included participation from Eli Lilly and Company and Ono Venture Investment alongside significant support from world-class existing investors.
Collaboration leverages OMass\u2019 OdyssionTM platform for the continued development of oral small molecules against a first-in-class target in inflammatory bowel disease. OMass to receive $20M upfront payment, with potential for more than $400M in additional milestone payments, as well as tiered royalties on net sales.
OXFORD UK: Moa Technology today announces its discovery of chemistries which could become an entirely new category of products to help farmers protect their harvests more safely, sustainably and effectively.
Infinitopes has achieved the gold standard among the latest awardees for the Laboratory Efficiency Assessment Framework (LEAF), an innovative initiative to improve laboratory efficiency. As the second BioEscalator tenant to earn this accreditation, they follow in the footsteps of 2023/24 winner, Exogene.
We\u2019re proud to celebrate the graduation of Alethiomics, a University of Oxford spin-out dedicated to developing innovative treatments for blood cancers, as they move from the BioEscalator to their new home at Abingdon Science Park.
Theolytics has created an extensive proprietary library of oncolytic viruses (viruses that kill cancer cells) to harness their potential to safely target and destroy tumour cells while leaving healthy cells intact.
Infinitopes received Innovate UK funding through the Investor Partnership Programme, which was pivotal to building and testing their cutting-edge discovery platform, and the Cancer Therapeutics Programme, to design, prepare and execute its phase I clinical trial, that scientists hope will be practice-changing.
OMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee.
![\"\"](\"https://www.bioescalator.ox.ac.uk/news-and-events/news/simon-meier-will-be-joining-oxford-cancer-analytics-oxcan-as-incoming-interim-ceo/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n